Last reviewed · How we verify
Adapalen
At a glance
| Generic name | Adapalen |
|---|---|
| Sponsor | Technische Universität Dresden |
| Target | Aspartate aminotransferase, cytoplasmic, Glycine receptor subunit alpha-1, Retinoic acid receptor alpha |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Acne vulgaris
Common side effects
- Scaling
- Dryness
- Erythema
- Burning/Stinging (persistent)
- Pruritis (persistent)
- Sunburn
- Skin discomfort-burning and stinging
- Skin irritation
- Scaling
- Dryness
- Erythema
- Pruritis (persistent)
Serious adverse events
- Erythema
- Scaling
- Dryness
- Pruritis (persistent)
- Burning/Stinging (persistent)
- Acne flare
- Dermatitis
- Contact dermatitis
- Eyelid edema
- Conjunctivitis
Key clinical trials
- Adjunctive Usage of a Moisturizing Lotion (Cetaphil® Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-Up of a Treatment by Topical Retinoid (Differin® Gel 0,1%) in Healthy Subjects of Chinese Origins (PHASE4)
- Pilot Study of Tolerability and Effectivity of Two Combination Topical Acne Products (PHASE4)
- Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adapalen CI brief — competitive landscape report
- Adapalen updates RSS · CI watch RSS
- Technische Universität Dresden portfolio CI